Vancouver, British Columbia – TheNewswire – January 10, 2022 – Lexston Life Sciences Corp. (the “Firm” or “Lexston”) (CSE:LEXT) (CNSX:LEXT.CN) (OTC:LEXTF) is happy to announce the signing of a Memorandum of Understanding (the “MOU”) between its wholly owned subsidiary Egret Bioscience Ltd. (“Egret”) and Panacea Plant Sciences Inc. (“Panacea”), a number one United States biotechnology firm targeted on creating new therapeutic, cultivation, extraction and isolation methods for top worth pure merchandise equivalent to psychedelic-containing lifeforms and hashish.
Underneath the phrases of the MOU, Panacea and Egret intend to create joint ventures (“JV”) by which they plan to broaden the provision chain, scale back the provision value, and characterize the chemistry and pharmacology of a collection of psychedelic compounds utilizing every group’s specific experience. The purpose of the JVs will probably be to develop cell-based tradition methods for the standardized manufacturing and formulation of novel psychedelic combos. Along with assigning mental property to the JV, the events can even assign 4 % (4%) of its fairness to environmental and indigenous teams related to the lifeform or compound of curiosity.
The groups just lately launched an preliminary pilot research on allosteric modulators of the serotonin receptor 5HT2A together with DMT, 5-Meo-DMT, mescaline, LSD, and psilocin. This work will determine the mechanisms for the entourage impact of psychedelic plant and fungi.
“We’re excited to proceed our collaboration efforts with Panacea. This settlement is important for Lexston because it permits us to broaden on our experience within the chemical and genetic analyses of pure merchandise to classical psychedelics. Involving the indigenous teams is a vital facet to each corporations because it encourages acceptance of our analysis and may doubtlessly enhance many lives.” States Dr. Philippe Henry, Chief Science Officer and Director of Lexston.
The events can even discover totally different botanical sources of naturally derived tryptamines to determine ultimate candidates for conventional and cell culture-based manufacturing. The analysis is anticipated to result in low-cost manufacturing of psychedelic compounds which can scale back prices for researchers in addition to sufferers as soon as these things are authorised by regulators.
Each events maintain licenses of their respective jurisdictions for scientific analysis on hashish and are candidates for psychedelic analysis licenses with the US DEA and Well being Canada. The events have additionally entered into a cloth switch settlement wherein Panacea will switch key germplasm for botanicals containing uncontrolled tryptamines and phenethylamines equivalent to Lophophora williamsii, Echinopsis pachanoi, Pterocarpus santalinus and Anadenantherra peregrina to Lexston for the optimization of plant tissue and cell tradition methodologies alongside chemical and genetic characterization of the Panacea germplasm.
For more information and to subscribe to the Company’s mailing list, please visit https://lexston.ca/contact/ .
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology firm offering hashish testing and analysis providers. Lexston can be within the strategy of securing licensing below the exemptions prescribed by part 56 of the Managed Medication and Substances Act (Canada) to allow the enlargement of its providers into the psychedelic trade with an preliminary concentrate on the detection and quantification of psychedelic molecules within the lab and level of care. Lexston intends to develop and validate strategies for standardized manufacturing of plant derived psychedelics in assist of burgeoning trials within the area of psychological well being and wellness.
On Behalf of the Board of Administrators
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Govt Officer
Phone: (604) 928-8913
This information launch accommodates forward-looking statements and knowledge inside the which means of relevant securities laws. Typically, however not at all times, forward-looking statements and knowledge will be recognized by way of phrases equivalent to “plans”, “expects” or “doesn’t anticipate”, “is anticipated”, “estimates”, “intends”, “anticipates” or “doesn’t anticipate”, or “believes”, or variations of such phrases and phrases or state that sure actions, occasions or outcomes “might”, “might”, “would”, “may” or “will” be taken, happen or be achieved. Ahead wanting statements or data contain recognized and unknown dangers, uncertainties and different components which can trigger the precise outcomes, efficiency, or achievements of LEXT to be materially totally different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements or data contained on this information launch.
Dangers, uncertainties, and different components concerned with forward-looking data might trigger precise occasions, outcomes, efficiency, prospects, and alternatives to vary materially from these expressed or implied by such forward-looking data. The Canadian Securities Alternate has not reviewed and doesn’t settle for accountability for the adequacy or accuracy of the content material of this information launch.